Astek Diagnostics has developed a platform for rapid antibiotic sensitivity testing. Every year, 1.7 million Americans are evaluated for sepsis - and too many die while waiting days for the correct antibiotic. Our platform determines antibiotic sensitivity in one hour.
Primary Application Area: Medical Devices & Materials
Technology Development Status: Prototype
Technology Readiness Level: TRL 4
Vetted Programs/Awards: Y Combinator, Summer 21 cohort
Harvard Capital Seed Fund
TEDCO MII and Builder Funds
SBIR Phase I grant
Mayland Industrial Partnerships Program(MIPS)
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: T52
GOVT/EXTERNAL FUNDING SOURCES
External Funding to Date: Astek has been awarded $315K Maryland’s MII program, and has an active Phase 1 SBIR award ($255K). Astek joined Summer 2021 cohort at the Y Combinator accelerator ($125K investment). Astek received $100K from Harvard. Astek also received $100K from The Mayland Industrial Partnerships (MIPS), and $500K from angel investors.